Antibe Therapeutics Inc. | |
Stock Exchange | Other OTC |
EPS |
$0.04 |
Market Cap |
$60.1 M |
Shares Outstanding |
111.68 M |
Public Float |
- |
Antibe Therapeutics Inc. | |
Stock Exchange | Toronto Ventures Stock Exchange |
EPS |
CAD0.05 |
Market Cap |
CAD78.5 M |
Shares Outstanding |
245.31 M |
Public Float |
201.67 M |
Address |
15 Prince Arthur Avenue Toronto Ontario M5R 1B2 Canada |
Employees | - |
Website | http://www.antibethera.com |
Updated | 07/08/2019 |
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the research and development of medicines for pain and inflammation. Its lead drug, ATB-346, targets the need for a safer non-steroidal anti-inflammatory drug for treating chronic pain and inflammation with non-addictive medication. It operates through the Antibe and Citagenix segment. |